No Data Yet
Absci Corporation reported positive preclinical data for ABS-201, a treatment targeting hair loss by regenerating the follicle stem cell niche. This positions the company to compete in the growing science-backed, premium haircare market.
Absci Independent Director François van Houten has acquired US$149k in company stock, increasing his personal holding by 454%. This significant insider purchase is a strong bullish signal, suggesting a high level of confidence in the company's future performance from its leadership.
Portfolio
